Lipoprotein Management in Patients With Cardiometabolic Risk
Authors:
Top Cited Papers
Abstract
No abstract availableFunding Information
- AstraZeneca
- Merck
- Abbott Laboratories
- Pfizer
- Novo Nordisk
This publication has 90 references indexed in Scilit:
- LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL managementJournal of Clinical Lipidology, 2007
- High-Density Lipoprotein as a Therapeutic TargetJAMA, 2007
- The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependentAtherosclerosis, 2007
- Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and WomenJACC, 2007
- Characteristics and Baseline Clinical Predictors of Future Fatal Versus Nonfatal Coronary Heart Disease Events in Older AdultsCirculation, 2006
- Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) IIAmerican Heart Journal, 2006
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Optimal low-density lipoprotein is 50 to 70 mg/dlJACC, 2004
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987